ENDRA Life Sciences Inc. Annual Report: A Performance Summary

I’ve put together this guide to help you understand ENDRA Life Sciences. Instead of digging through dense legal filings, I’ve broken down the key points here in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

ENDRA is a medical tech company building TAEUS®, a device that acts like an "enhanced" ultrasound. Standard ultrasounds show organ structure, but they struggle to measure liver fat. ENDRA’s tech uses radio frequency pulses to "see" tissue chemistry. This helps doctors track metabolic diseases like liver fat buildup without the high cost of an MRI or the pain of a biopsy. The company has not yet made meaningful sales and is still working toward regulatory approval.

2. The Financial Reality: A "Going Concern" Warning

The most important point is that auditors have raised "substantial doubt" about the company’s ability to stay in business. As of December 31, 2024, they reported a total loss of $110.4 million over the years. The company is in "survival mode." They cut their staff to just four full-time employees in early 2025 to slow their monthly cash burn of $400,000 to $500,000. They are currently looking for a buyer or merger partner because they lack the cash to fund operations for long.

3. A New, Unusual Strategy: Crypto

The company has adopted a "Digital Asset Treasury Strategy." They invested some of their limited cash into cryptocurrency, specifically $HYPE tokens and decentralized finance protocols. This is a major departure from typical biotech management. By holding these volatile assets, the company has added significant risk to its balance sheet. The value of their treasury now rises and falls with the crypto market. Management warns that this could cause extreme swings in the stock price.

4. Future Outlook: The GLP-1 Opportunity

ENDRA is betting its future on the popularity of weight-loss drugs like Ozempic. As patients lose weight, doctors need a cheap, non-invasive way to monitor liver fat. ENDRA positions TAEUS® as a cheaper alternative to $1,500–$2,500 MRI scans. However, the company has paused the clinical trials needed for FDA approval. Without money to fund these trials, their path to selling the device in the U.S. remains stalled.

5. Key Risks to Your Investment

• Liquidity Crisis: With almost no cash and no sales, the company faces an immediate risk of running out of money. If they cannot find a partner or raise more cash, they may have to shut down or file for bankruptcy.
• Nasdaq Delisting: The stock has struggled to stay above the $1.00 minimum price required by Nasdaq. A delisting would make it harder to trade your shares and harder for the company to raise money.
• The Crypto Gamble: Holding crypto adds technical and regulatory risk. If the crypto market crashes, the company’s remaining cash reserves could shrink significantly.
• Regulatory Hurdles: TAEUS® lacks FDA clearance. The approval process is expensive and slow. Any further delays will prevent the company from ever generating sales.
• Dilution: To survive, the company has frequently issued more shares to raise cash. This reduces your ownership percentage and often lowers the stock price.

Final Thought for Investors: ENDRA is currently a high-risk, speculative situation. Because the company is actively seeking a buyer or merger partner and has paused its core clinical operations, the primary value proposition is tied to a potential acquisition or a successful pivot. Before considering an investment, weigh whether you are comfortable with the risks of a company that is essentially in a "survival" phase, heavily reliant on volatile crypto assets, and currently lacking the capital to bring its primary product to market.